根治性膀胱切除术后因异时性复发行根治性肾输尿管切除术的全尿路上皮癌患者的临床结局
本研究回顾性分析1995年1月至2014年12月在本机构接受根治性膀胱切除术后因异时性尿路上皮癌复发行根治性肾输尿管切除术的64例患者,中位年龄66岁,中位间隔2.7年。根治性肾输尿管切除术后病理显示39%为局部晚期(pT3/pT4),11%淋巴结阳性;术后96%患者eGFR<60、40%<30 ml/min/1.73 m2;中位总生存3.1年,仅肾输尿管切除时淋巴结受累与更差总生存显著相关(HR 2.73)。
要点
- 膀胱切除术后异时性复发行肾输尿管切除者局部晚期比例高(39% pT3/pT4,11%淋巴结阳性)。
- 术后肾功能显著下降,96%患者eGFR<60、40%<30 ml/min/1.73 m2,几乎均不适合顺铂化疗。
- 肾输尿管切除术后中位总生存3.1年,仅淋巴结受累与更差总生存显著相关(HR 2.73)。
核心结论
- 全尿路上皮癌患者膀胱切除术后行肾输尿管切除术预后差,大部分为局部晚期疾病。
- 术后肾功能减退,几乎所有患者不适合以顺铂为基础的化疗。
研究设计与样本
- 回顾性研究,纳入本机构1995年1月至2014年12月接受根治性膀胱切除术后因异时性尿路上皮癌复发行根治性肾输尿管切除术的患者。
- 3173例接受根治性膀胱切除术的患者中64例后续行根治性肾输尿管切除术。
- 采用单变量Cox回归评估总生存与年龄、分级、分期、淋巴结转移及影像学表现之间的关联。
主要发现
- 根治性膀胱切除术时中位年龄66岁(IQR 61-74);64例患者从膀胱切除至肾输尿管切除的中位时间为2.7年(IQR 1.4-4.6)。
- 37例在肾输尿管切除术前接受输尿管镜检查,其中29例(78%)活检阳性。
- 肾输尿管切除术后病理显示局部晚期(pT3/pT4)占39%、淋巴结阳性占11%;膀胱切除术后病理显示局部晚期占17%、淋巴结阳性占6%。
- 肾输尿管切除术后eGFR<60 ml/min/1.73 m2者占96%,<30 ml/min/1.73 m2者占40%。
- 肾输尿管切除术后中位总生存3.1年(95% CI 2.4-4.3);仅肾输尿管切除时淋巴结受累与更差总生存显著相关(HR 2.73,95% CI 1.04-7.15,p=0.041)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report pathological, functional and oncologic outcomes in patients treated with radical nephroureterectomy following radical cystectomy. MATERIALS AND METHODS: We identified patients who underwent radical cystectomy and then radical nephroureterectomy for metachronous urothelial recurrence at our institution between January 1995 and December 2014. Univariable Cox regression was used to assess the association between overall survival and age, grade, stage, lymph node metastasis and radiographic findings. RESULTS: Of the 3,173 patients treated with radical cystectomy 64 underwent subsequent radical nephroureterectomy for metachronous urothelial recurrence. Median age at radical cystectomy was 66 years (IQR 61-74). In the 64 patients who underwent radical nephroureterectomy median time from radical cystectomy to radical nephroureterectomy was 2.7 years (IQR 1.4-4.6). Among 37 patients who underwent ureteroscopy prior to radical nephroureterectomy 29 (78%) had a positive biopsy. Radical nephroureterectomy pathology findings revealed locally advanced disease (pT3/pT4) in 39% of cases and positive node status in 11% compared with locally advanced disease in 17% and positive node status in 6% on radical cystectomy pathology findings. The post-radical nephroureterectomy estimated glomerular filtration rate was less than 60 and less than 30 ml/minute/1.73 m2 in 96% and 40% of patients, respectively. Median overall survival after radical nephroureterectomy was 3.1 years (95% CI 2.4-4.3). Only lymph node involvement at radical nephroureterectomy was significantly associated with worse overall mortality (HR 2.73, 95% CI 1.04-7.15, p = 0.041). CONCLUSIONS: The prognosis is poor in patients with panurothelial carcinoma treated with nephroureterectomy following cystectomy with locally advanced disease in a large proportion. Renal function after these procedures diminished and almost all patients were ineligible for cisplatin based chemotherapy.
引用
- Li Q, Assel M, Benfante N, et al. Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. J Urol. 2017. PMID: 28342936. doi:10.1016/j.juro.2017.03.120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。